1. Home
  2. ALHC vs MPLT Comparison

ALHC vs MPLT Comparison

Compare ALHC & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alignment Healthcare Inc.

ALHC

Alignment Healthcare Inc.

N/A

Current Price

$7.43

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

N/A

Current Price

$7.27

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALHC
MPLT
Founded
2013
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
ALHC
MPLT
Price
$7.43
$7.27
Analyst Decision
Buy
Strong Buy
Analyst Count
15
15
Target Price
$10.79
★ $26.54
AVG Volume (30 Days)
★ 5.2M
338.2K
Earning Date
10-29-2026
12-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 100.00
82.39
EPS
★ 0.19
N/A
Revenue
★ $3,948,719,000.00
N/A
Revenue This Year
$32.12
N/A
Revenue Next Year
$25.99
N/A
P/E Ratio
$39.29
★ N/A
Revenue Growth
★ 46.06
N/A
52 Week Low
$6.01
$6.06
52 Week High
$25.12
$40.43

Technical Indicators

Market Signals
Indicator
ALHC
MPLT
Relative Strength Index (RSI) 41.02 39.96
Support Level $7.14 $6.06
Resistance Level $8.66 $8.58
Average True Range (ATR) 0.51 0.57
MACD 0.06 0.15
Stochastic Oscillator 29.39 51.60

Price Performance

Historical Comparison
ALHC
MPLT

About ALHC Alignment Healthcare Inc.

Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: